Inventiva’s Financial Position and Future Prospects

Inventiva (IVA) has released an update.

Inventiva, a clinical-stage biopharmaceutical company, has reported a cash position of €13.9 million as of September 2024, with revenues reaching €1.3 million for the first nine months of 2024. The company successfully raised €94.1 million as part of an equity financing initiative, expected to fund operations until mid-2025, and noted a strategic focus on advancing the Phase 3 trial of its lead product candidate, lanifibranor, for MASH/NASH treatment.

For further insights into IVA stock, check out TipRanks’ Stock Analysis page.